Lerodalcibep, a third-generation PCSK9 inhibitor, reduced LDL by more than 50% vs placebo in patients with or at a high risk for CVD in the phase 3 LIBerate-HR trial.
A randomized crossover study using snacks with a particular constellation of nutrients including fiber, antioxidants, and phytosterols reduced LDL compared with snacks with similar calories.
Less Care for Young Women With Chest Pain in the Emergency n? medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.